Free Trial
NASDAQ:VRDN

Viridian Therapeutics Q1 2025 Earnings Report

Viridian Therapeutics logo
$12.29 +0.26 (+2.16%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$12.42 +0.14 (+1.10%)
As of 06:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics EPS Results

Actual EPS
-$0.87
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Viridian Therapeutics Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
$0.16 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Viridian Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Viridian Therapeutics' Q2 2025 earnings is scheduled for Wednesday, May 14, 2025

Viridian Therapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Viridian Therapeutics appoints Ajer to its board of directors
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN), a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

View Viridian Therapeutics Profile

More Earnings Resources from MarketBeat